SNCE SCIENCE 37 HLDGS INC

Science 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx Conference

Science 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Science 37® Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the company will be participating in the upcoming 5th Annual Evercore ISI HealthCONx Conference.

Science 37’s management is scheduled to participate virtually in a fireside chat on Thursday, December 1, 2022, at 8:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at:

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit

MEDIA INQUIRIES:

Grazia Mohren Science 37

Email:

INVESTOR RELATIONS:

Steven Halper

LifeSci Advisors



EN
30/11/2022

Underlying

SNCESCIENCE 37 HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Completes Third FDA Inspection, Validating Quality of its D...

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review cen...

October 8, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 and Catalent Announce Partnership Enabling Universal Access...

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , the leader in expanding patient access to clinical trials, and ®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

April 8, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

January 14, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

November 21, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch